Arvinas Stock Forecast, Price & News

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arvinas in the last year. There are currently 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arvinas stock.
View analyst ratings for Arvinas or view top-rated stocks.

Wall Street analysts have given Arvinas a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Arvinas wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Arvinas is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Arvinas.

Arvinas, Inc. (NASDAQ:ARVN) posted its quarterly earnings results on Wednesday, August, 4th. The company reported ($1.03) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.86) by $0.17. The company had revenue of $5.54 million for the quarter, compared to the consensus estimate of $5.39 million. Arvinas had a negative net margin of 782.95% and a negative trailing twelve-month return on equity of 31.99%.
View Arvinas' earnings history.

Arvinas' stock was trading at $44.06 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ARVN stock has increased by 109.5% and is now trading at $92.29.
View which stocks have been most impacted by COVID-19.

14 brokers have issued 12-month price targets for Arvinas' stock. Their forecasts range from $93.00 to $170.00. On average, they expect Arvinas' share price to reach $130.36 in the next year. This suggests a possible upside of 41.2% from the stock's current price.
View analysts' price targets for Arvinas or view top-rated stocks among Wall Street analysts.

Some companies that are related to Arvinas include Viatris (VTRS), Elanco Animal Health (ELAN), BioMarin Pharmaceutical (BMRN), Maravai LifeSciences (MRVI), Zai Lab (ZLAB), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Grifols (GRFS), CureVac (CVAC), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND) and Biohaven Pharmaceutical (BHVN).
View all of ARVN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Arvinas investors own include Dynavax Technologies (DVAX), ImmunoGen (IMGN), Pfizer (PFE), CRISPR Therapeutics (CRSP), Energy Transfer (ET), OPKO Health (OPK), Advanced Micro Devices (AMD), Enphase Energy (ENPH), Fortress Biotech (FBIO) and Gilead Sciences (GILD).

(ARVN) raised $100 million in an IPO on Thursday, September 27th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. Goldman Sachs, Citigroup and Piper Jaffray served as the underwriters for the IPO.

Arvinas trades on the NASDAQ under the ticker symbol "ARVN."

Arvinas' stock is owned by a number of institutional and retail investors. Top institutional investors include FMR LLC (12.16%), Vanguard Group Inc. (7.46%), BlackRock Inc. (6.35%), Price T Rowe Associates Inc. MD (5.04%), Bellevue Group AG (4.55%) and New Leaf Venture Partners L.L.C. (4.50%). Company insiders that own Arvinas stock include Bradley Albert Margus, Briggs Morrison, Ian Taylor, John G Houston, John G Houston, Liam Ratcliffe, Ronald Peck, Sean A Cassidy and Timothy M Shannon.
View institutional ownership trends for Arvinas.

ARVN stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Marshall Wace LLP, Marshall Wace North America L.P., 5AM Venture Management LLC, ArrowMark Colorado Holdings LLC, Healthcare of Ontario Pension Plan Trust Fund, New Leaf Venture Partners L.L.C., and Renaissance Technologies LLC. Company insiders that have sold Arvinas company stock in the last year include Bradley Albert Margus, Ian Taylor, John G Houston, Ronald Peck, and Sean A Cassidy.
View insider buying and selling activity for Arvinas or view top insider-selling stocks.

ARVN stock was purchased by a variety of institutional investors in the last quarter, including FMR LLC, Vanguard Group Inc., Deutsche Bank AG, Morgan Stanley, Morgan Stanley, Bellevue Group AG, Invesco Ltd., and BlackRock Inc.. Company insiders that have bought Arvinas stock in the last two years include Briggs Morrison, Liam Ratcliffe, and Timothy M Shannon.
View insider buying and selling activity for Arvinas or or view top insider-buying stocks.

Shares of ARVN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ARVN stock can currently be purchased for approximately $92.29.

Arvinas has a market capitalization of $4.54 billion and generates $21.80 million in revenue each year. The company earns $-119,330,000.00 in net income (profit) each year or ($3.02) on an earnings per share basis.

Arvinas employs 179 workers across the globe.

The official website for Arvinas is www.arvinas.com.

Arvinas is headquartered at 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511.

Arvinas' mailing address is 5 SCIENCE PARK 395 WINCHESTER AVE, NEW HAVEN CT, 06511. The company can be reached via phone at (203) 535-1456 or via email at [email protected].